References
- WernerFMCoveñasRSafety of antipsychotic drugs: focus on therapeutic and adverse effectsExp Opin Drug Saf201413810311042
- KlosterkötterJIndicated prevention of schizophreniaDtsch Arztebl Int20081053053253919626210
- WernerF-MCoveñasRClassical neurotransmitters and neuropeptides involved in schizophrenia: how to choose the appropriate antipsychotic drug?Curr Drug Ther201382132143
- VasilyevaIBiscontriRGEnnsMWMetgeCJAlessi-SeveriniSMovement disorders in elderly users of risperidone and first generation antipsychotic agents: a Canadian population-based studyPLoS One201385e6421723696870
- McEvoyJPEfficacy of risperidone on positive features of schizophreniaJ Clin Psychiatry199455Suppl18217520904
- MaedaKLerdrupLSuginoHBrexpiprazole II: antipsychotic-like and precognitive effects of a novel serotonin-dopamine activity modulatorJ Pharmacol Exp Ther2014250360561424947464
- KorteSMPrinsJKrajncAMThe many different faces of major depression: it is time for personalized medicineEur J Pharmacol20157538810425592320
- CacciaSInvernizziRWNobiliAPasinaLA new generation of antipsychotics: pharmacology and clinical utility of cariprazine in schizophreniaTher Clin Risk Manag2013931932823966785
- WernerFMCoveñasRClassical neurotransmitters and neuropeptides involved in major depression: a reviewInt J Neurosci2010120745547020583898
- RybakowskiJKGenetic influences on response to mood stabilizers in bipolar disorder: current status of knowledgeCNS Drugs201327316517323378337
- MulaMCavannaAEMonacoFPsychopharmacology of topiramate: from epilepsy to bipolar disorderNeuropsychiatr Dis Treat20062447548819412496
- Pilla ReddyVKozielskaMSuleimanAAPharmacokinetic-pharmacodynamic modeling of antipsychotic drugs in patients with schizophrenia. Part I: the use of PANSS total score and clinical utilitySchizophr Res20131461–314415223473810
- RihmenZGondaXKálmánJTreatment of bipolar disorder with lamotrigine relapse and suicidal behaviour during 6 month follow-upNeuropsychopharmacol Hung201517171325935378
- CalabresiPPicconiBTozziAGhiglieriVInteraction between basal ganglia and limbic circuits in learning and memory processesParkinsonism Relat Disord Epub201595
- DurgamSStaraceAMiglioreRRuthANémethGLaszlovszkyIAn evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized, clinical trialSchizophr Res20141522–345045724412468
- DüringSGlenthojBYAndersenGSOranjeBEffects of dopamine D2/D3 blockade on human sensory and sensorimotor gating in initially antipsychotic-naive, first-episode schizophrenia patientsNeuropsychopharmacology201439133000300824954063
- CitromeLCariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerabilityExpert Opin Drug Metabol Toxicol201392193206
- VeselinovicTPaulzenMGrunderGCariprazine, a new, orally active dopamine D2/3 receptor partial agonist for the treatment of schizophrenia, bipolar mania and depressionExpert Rev Neurother201313111141115924175719
- AltinbasKGuloksuzSOralETClinical potential of cariprazine in the treatment of acute maniaPsychiatr Danub201325320721324048386
- ZukinSRKaneJCutlerAJEfficacy and safety of cariprazine in acute exacerbation of schizophrenia: a phase III, international, randomized, double-blind, placebo-controlled trialNeuropsychopharmacology201238Suppl 1S319
- DaumitGIGoffDCMeyerJMAntipsychotic effect on estimated 10-year coronary heart disease risk in the CATIE schizophrenia studySchizophr Res20081051–317518718775645
- GyertyánIKissBSaghyKCariprazine (RGH-188), a potent D2/D3 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodentsNeurochem Int200859692593521767587
- KolotkinRLCorey-LislePKCrosbyRDImpact of obesity on health-related quality of life in schizophrenia and bipolar disorderObesity (Silver Spring)200816474975418239573
- KissBHorváthANémethyZCariprazine, (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profileJ Pharmacol Exp Ther2010333132834020093397
- SenecaNFinnemaSJLaszlovskyIOccupancy of D2 and D3 and serotonin 5-HT1A receptors by the novel antipsychotic drug candidate cariprazine (RGH-188), in monkey brain measured using positron emission tomographyPsychopharmacology (Berl)2011218357958721625907